Firoozeh Sahebi, M.D.

(877) 460-4673
Firoozeh Sahebi, M.D.
Hematologist
Clinical Expertise
  • Bone Marrow Transplantation
Research Area
  • Hematology and Hematopoietic Cell Transplantation
Academic Appointments
  • Professor, Department of Hematology & Hematopoietic Cell Transplantation
Clinical Teams
Hematology & Hematopoietic Cell Transplantation — Kaiser
Myeloma and Multiple Myeloma
Research Teams
Cellular Immunotherapy
Firoozeh Sahebi, M.D., is a board-certified hematologist specializing in Bone Marrow Transplant and Cancer Cellular Immunotherapy.  She is also a member of the City of Hope/Kaiser Bone Marrow Transplantation Team.
 
Dr. Sahebi obtained her medical degree from School of Medicine at Tehran University. She completed her residency in Internal Medicine at Nassau County Medical Center in East Meadow, NY. She then moved on to complete fellowships in Hematology/Oncology at Columbia University and UCLA Medical Center.
 
She is a member of multiple institutional committees at City of Hope and Southern California Kaiser Permanente. She has published  several peer reviewed journals and presented her research at American Society of Hematology and European Society for Blood and Marrow Transplantation meetings. 
 
Dr. Sahebi enjoys spending time with her family, painting, yoga and her book club.

Location

Education & Experience

Board Certifications

  • American Board of Hematology

Degrees

  • 1987, M.D., Tehran University, School of Medicine, Tehran, Iran

Fellowship

  • 1992-1994, Divisions of Hematology /Oncology, UCLA Medical Center, Los Angeles, CA

  • 1991-1992, Divisions of Hematology/ Oncology, Columbia University, College of Physicians & Surgeons, Presbyterian Hospital, New York, NY

Residency

  • 1988-1991, Nassau County Medical Center, Affiliate of State University of New York at Stony Brook, New York, NY

Professional Experience

  • 1998-present, Professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA

  • 1994-present, Staff Physician, Division of Bone Transplantation and Hematology/Oncology, Kaiser Hospital, Los Angeles, CA

Awards & Memberships

Awards

  • 11/2013, Walter Lusk Award Distinguished Physician Award for excellence in compassionate care and outstanding communication with patients

  • 1994-1999, UCLA Teaching Appreciation Award

Publications

  • Herrera AF, Chen L, Nieto Y, Holmberg L, Johnston P, Mei M, Popplewell L, Armenian S, Cao T, Farol L, Sahebi F, Spielberger R, Chen R, Nademanee A, Puverel S, Nwangwu M, Lee P, Song J, Skarbnik A, Kennedy N, Peters L, Rosen ST, Kwak LW, Forman SJ, Feldman T. Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial. Lancet Haematol. 2023 Jan;10(1):e14-e23. doi: 10.1016/S2352-3026(22)00318-0. Epub 2022 Nov 17. PMID: 36403579.
  • Ladbury C, Somlo G, Dagis A, Yang D, Armenian S, Song JY, Sahebi F, Spielberger R, Popplewell L, Parker P, Forman S, Snyder D, Rincon A, Liu A, Frankel P, Wong J. Long-Term Follow-Up of Multiple Myeloma Patients Treated with Tandem Autologous Transplantation Following Melphalan and Upon Recovery, Total Marrow Irradiation. Transplant Cell Ther. 2022 Jul;28(7):367.e1-367.e9. doi: 10.1016/j.jtct.2022.04.022. Epub 2022 May 6. PMID: 35534000.
  • Herrera AF, Palmer J, Adhikarla V, Yamauchi D, Poku EK, Bading J, Yazaki P, Dandapani S, Mei M, Chen R, Cao T, Karras N, McTague P, Nademanee A, Popplewell L, Sahebi F, Shively JE, Simpson J, Smith DL, Song J, Spielberger R, Tsai NC, Thomas SH, Forman SJ, Colcher D, Wu AM, Wong J, Smith E. Anti-CD25 radioimmunotherapy with BEAM autologous hematopoietic cell transplantation conditioning in Hodgkin lymphoma. Blood Adv. 2021 Dec 14;5(23):5300-5311. doi: 10.1182/bloodadvances.2021004981. PMID: 34638132; PMCID: PMC9153018.
  • Sahebi F, Eikema DJ, Koster L, Kroger N, Meijer E, van Doesum JA, Rovira M, Koc Y, Angelucci E, Blaise D, Sammassimo S, McDonald A, Arroyo CH, Sanchez JF, Forcade E, Castagna L, Stölzel F, Sanz J, Tischer J, Ciceri F, Valcarcel D, Proia A, Hayden PJ, Beksac M, Yakoub-Agha I, Schönland S. Post-Transplantation Cyclophosphamide for Graft-versus- Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison by Donor Type. A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. Transplant Cell Ther. 2021 Dec;27(12):999.e1-999.e10. doi: 10.1016/j.jtct.2021.09.008. Epub 2021 Sep 17. PMID: 34543768.
  • Krishnan A, Adhikarla V, Poku EK, Palmer J, Chaudhry A, Biglang-Awa VE, Bowles N, Nathwani N, Rosenzweig M, Sahebi F, Karanes C, Simpson J, Sanchez JF, Yamauchi D, Parayno M, Chowdhury A, Caserta E, Marcucci G, Rockne R, Wu AM, Wong J, Forman SJ, Colcher D, Yazaki P, Shively J, Pichiorri F. Identifying CD38+ cells in patients with multiple myeloma: first-in-human imaging using copper-64-labeled daratumumab. Blood Adv. 2020 Oct 27;4(20):5194-5202. doi: 10.1182/bloodadvances.2020002603. PMID: 33095874; PMCID: PMC7594407.
  • Krishnan A, Adhikarla V, Poku EK, Palmer J, Chaudhry A, Biglang-Awa VE, Bowles N, Nathwani N, Rosenzweig M, Sahebi F, Karanes C, Simpson J, Sanchez JF, Yamauchi D, Parayno M, Chowdhury A, Caserta E, Marcucci G, Rockne R, Wu AM, Wong J, Forman SJ, Colcher D, Yazaki P, Shively J, Pichiorri F. Identifying CD38+ cells in patients with multiple myeloma: first-in-human imaging using copper-64-labeled daratumumab. Blood Adv. 2020 Oct 27;4(20):5194-5202. doi: 10.1182/bloodadvances.2020002603. PMID: 33095874; PMCID: PMC7594407.
  • Cooper JP, Storer BE, Granot N, Gyurkocza B, Sorror ML, Chauncey TR, Shizuru J, Franke GN, Maris MB, Boyer M, Bruno B, Sahebi F, Langston AA, Hari P, Agura ED, Lykke Petersen S, Maziarz RT, Bethge W, Asch J, Gutman JA, Olesen G, Yeager AM, Hübel K, Hogan WJ, Maloney DG, Mielcarek M, Martin PJ, Flowers MED, Georges GE, Woolfrey AE, Deeg JH, Scott BL, McDonald GB, Storb R, Sandmaier BM. Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: Improved outcomes over two decades. Haematologica. 2021 Jun 1;106(6):1599-1607. doi: 10.3324/haematol.2020.248187. PMID: 32499241; PMCID: PMC8168504.
  • Rosenzweig M, Palmer J, Tsai NC, Synold T, Wu X, Tao S, Hammond SN, Buettner R, Duarte L, Htut M, Karanes C, Nathwani N, Pichiorri F, Sahebi F, Sanchez JF, Chowdhury A, Krishnan A, Forman SJ, Rosen ST. Repurposing leflunomide for relapsed/refractory multiple myeloma: a phase 1 study. Leuk Lymphoma. 2020 Jul;61(7):1669-1677. doi: 10.1080/10428194.2020.1742900. Epub 2020 Apr 8. PMID: 32268821; PMCID: PMC7384948.
  • Pourmoussa AM, Spielberger R, Cai J, Khoshbin O, Farol L, Cao T, Sahebi F. Predictive Factors for Early Relapse in Multiple Myeloma after Autologous Hematopoietic Stem Cell Transplant. Perm J. 2019;23:19.012. doi: 10.7812/TPP/19.012. Epub 2019 Oct 11. PMID: 31926575; PMCID: PMC6836627.
  • Giralt S, Costa LJ, Maloney D, Krishnan A, Fei M, Antin JH, Brunstein C, Geller N, Goodman S, Hari P, Logan B, Lowsky R, Qazilbash MH, Sahebi F, Somlo G, Rowley S, Vogl DT, Vesole DH, Pasquini M, Stadtmauer E. Tandem Autologous-Autologous versus Autologous-Allogeneic Hematopoietic Stem Cell Transplant for Patients with Multiple Myeloma: Long-Term Follow-Up Results from the Blood and Marrow Transplant Clinical Trials Network 0102 Trial. Biol Blood Marrow Transplant. 2020 Apr;26(4):798-804. doi: 10.1016/j.bbmt.2019.11.018. Epub 2019 Nov 19. PMID: 31756536; PMCID: PMC7198329.
  • Sahebi F, Eikema D,  Koster L, Kröger N, Meijer E,  Choi G,  Rovira M, Koc Y, Angelucci E, Blaise D, Tarella C, et al. Post-Transplant Cyclophosphamide for Graft Vs Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison By Donor Type; A Study from the Chronic Malignancies Working Party of the EBMT, Blood (2020) 136 (Supplement 1): 1–2. 10.1182/blood-2020-137789
  • Giralt S, Costa LJ, Maloney D, Krishnan A, Fei M, Antin JH, Brunstein C, Geller N, Goodman S, Hari P, Logan B, Lowsky R, Qazilbash MH, Sahebi F, et al. Tandem Autologous-Autologous versus Autologous-Page 3 of 7
  • Allogeneic Hematopoietic Stem Cell Transplant for Patients with Multiple Myeloma: Long-Term Follow-Up Results from the Blood and Marrow Transplant Clinical Trials Network 0102 Trial. Biol Blood Marrow Transplant. 2020 Apr;26(4):798-804. doi: 10.1016/j.bbmt.2019.11.018. Epub 2019 Nov 19.Biol Blood Marrow Transplant. 2020. PMID: 31756536
  • Herrera A, Chen L, Nieto Y, Holmberg L, Johnston P, Mei M, Popplewell L, Armenian S, Cao T, Farol L, Sahebi F, et al. Consolidation with Nivolumab and Brentuximab Vedotin after Autologous Hematopoietic Cell Transplantation in Patients with High-Risk Hodgkin Lymphoma Blood (2020) 136 (Supplement 1): 19–20. Oral and Poster Abstracts Pourmoussa AM, Spielberger R, Cai J, Khoshbin O, Farol L, Cao T, Sahebi F. , et al. Predictive Factors for Early Relapse in Multiple Myeloma after Autologous Hematopoietic Stem Cell Transplant. Perm J. 2019;23:19.012. doi: 10.7812/TPP/19.012. Epub 2019 Oct 11.Perm J. 2019. PMID: 31926575
  • Giralt S, Costa LJ, Maloney D, Krishnan A, Fei M, Antin JH, Brunstein C, Geller N, Goodman S, Hari P, Logan B, Lowsky R, Qazilbash MH, Sahebi F, Somlo G, Rowley S, Vogl DT, Vesole DH, Pasquini M, Stadtmauer E. Tandem Autologous-Autologous versus Autologous-Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Multiple Myeloma: Long-term Follow-Up Results from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0102 Trial. Biol Blood Marrow Transplant. 2019 Nov 19. pii: S1083-8791(19)30785-2. doi: 10.1016/j.bbmt.2019.11.018. [Epub ahead of print] PMID: 31756536
  • Maffini E, Storer BE, Sandmaier BM, Bruno B, Sahebi F, Shizuru JA, Chauncey TR, Hari P, Lange T, Pulsipher MA, McSweeney PA, Holmberg L, Becker PS, Green DJ, Mielcarek M, Maloney DG, Storb R. Long-term Follow Up of Tandem Autologous-allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Haematologica. 2019 Feb;104(2):380-391. doi: 10.3324/haematol.2018.200253. [Epub 2018 Sep 27] PMID:30262560
  • Sahebi F, Garderet L, Kanate AS, Eikema DJ, Knelange NS, Alvelo OFD, Koc Y, Blaise D, Bashir Q, Moraleda JM, Dreger P, Sanchez JF, Ciurea S, Schouten H, Shah NN, Verbeek M, Rösler W, Diez-Martin JL, Schoenland S, D'Souza A, Kröger N, Hari P. Outcomes of Haploidentical Transplantation in Patients with Relapsed Multiple Myeloma: An EBMT/CIBMTR Report. Biol Blood Marrow Transplant. 2018 Sep 20. pii: S1083-8791(18)30575-5. doi: 10.1016/j.bbmt.2018.09.018. [Epub ahead of print] PMID:30243581
  • Sahebi F, Iacobelli S, Sbianchi G, Koster L, Blaise D, Reményi P, Russell NH, Ljungman P, Kobbe G, Apperley J, Trneny M, Krejci M, Wiktor-Jedrzejczak W, Sanchez JF, Schaap N, Isaksson C, Lenhoff S, Browne P, Scheid C, Wilson KMO, Yakoub-Agha I, Muñiz SG, Schönland S, Morris C, Garderet L, Kröger N. Incidence of Second Primary Malignancies after Autologous Transplantation for Multiple Myeloma in the Era of Novel Agents. Biol Blood Marrow Transplant. 2018 Jan 12. pii: S1083-8791(18)30021-1. doi: 10.1016/j.bbmt.2018.01.006. [Epub ahead of print] PMID:29339268
  • Herrera AF, Palmer J, Martin P, Armenian S, Tsai NC, Kennedy N, Sahebi F, Cao T, Budde LE, Mei M, Siddiqi T, Popplewell L, Rosen S, Kwak L, Nademanee A, Forman S, Chen R. Autologous Stem Cell Transplantation After Second Line Brentuximab Vedotin in Relapsed or Refractory Hodgkin Lymphoma. Ann Oncol. 2017 Dec 20. doi: 10.1093/annonc/mdx791. [Epub ahead of print] PMID:29272364 Krishnan A, Kapoor P, Palmer JM, Tsai NC, Kumar S, Lonial S, Htut M, Karanes C, Nathwani N, Rosenzweig M, Sahebi F, Somlo G, Duarte L, Sanchez JF, Auclair D, Forman SJ, Berdeja JG. Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma. Leukemia. 2017 Dec 18. doi: 10.1038/leu.2017.352. [Epub ahead of print] PMID: 29249822 Page 4 of 7
  • Stein A, Palmer J, Tsai NC, Al Malki MM, Aldoss I, Ali H, Aribi A, Farol L, Karanes C, Khaled S, Liu A, O'Donnell M, Parker P, Pawlowska A, Pullarkat V, Radany E, Rosenthal J, Sahebi F, Salhotra A, Sanchez JF, Schultheiss T, Spielberger R, Thomas SH, Snyder D, Nakamura R, Marcucci G, Forman SJ, Wong J. Phase I Trial of Total Marrow and Lymphoid Irradiation Transplantation Conditioning in Patients with Relapsed/Refractory Acute Leukemia. Biol Blood Marrow Transplant. 2017 Apr;23(4):618-624. doi: 10.1016/j.bbmt.2017.01.06

Ratings & Reviews

Ratings and reviews below are gathered from the Press Ganey Clinician and Group Consumer Assessment of Healthcare Providers and Systems (CG CAHPS) survey. CG CAHPS is a standardized survey that is used to measure a patient's experience in the physician office setting. Ratings are an average of all responses to questions about a provider's care, with five stars being the highest.
5.0
Spend enough time with you
4.9
Recommend this provider office
4.9
Provider explain in way you understand
4.9
Provider listen carefully to you
4.9
Know important info medical history
4.9
Show respect for what you say
4.9
Rate provider 0-10
03/09/26
We are already sharing with family and friends the City of Hope is special! - Verified patient
03/09/26
Dr. Sahebi talked with us not at us. She explained the cancer treatment so elementary, my wife said to me and my daughter I can do this, all praises to our Father in heaven! - Verified patient
01/20/26
Very organized personnel - Verified patient
01/20/26
Personnel here are amazing - Verified patient
11/16/25
Very good - Verified patient